In this study, patients with oligo-metastatic prostate cancer will be randomized to radical prostatectomy plus standard care and standard care only. Standard care refers to androgen deprivation therapy (ADT) +/- other systemic therapies. Time to disease progression and post-treatment quality of life will be assessed and compared.
Age
18–75
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Participants is willing and able to give informed consent for participation in the study
Male aged 19-75 years.
Diagnosed with oligo-metastatic prostate cancer (1-3 skeletal lesions on bone specific imaging, no visceral metastases).
